In a significant blow, Abbott Laboratories (NYSE:ABT) saw its shares nosedive following a U.S. jury’s ruling that found Abbott’s formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty. What Happened: As per Benzinga Pro, shares of Abbott Laboratories fell by 7.82%, trading at $97.01 during Monday’s pre-market session. This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival Reckitt Benckiser (OTC:RBGLY), or both, in U.S. federal or state courts. Enfamil formula maker Reckitt Benckiser’s shares also experie…
